Curis Inc. (CRIS) announced on Monday that its collaborator Genentech Inc. (DNA) has initiated a mid-stage trial of GDC-0449 as a maintenance therapy for ovarian cancer.
Curis said it will receive a cash payment of $3 million under a collaboration deal with Genentech.
GDC-0449 is an orally-administered small molecule Hedgehog pathway inhibitor. The phase II trial is designed to investigate if GDC-0449 may help delay tumor re-growth following clinical remission of cancer after second-line chemotherapy treatment for recurrent disease.
GDC-0449 will be evaluated in about 100 patients with ovarian cancer in second or third complete remission. The primary endpoint of the trial is progression-free survival. Secondary outcome measures include overall survival, measurement of Hedgehog ligand expression in archival tissue and number and attribution of adverse events.
Under the ongoing collaboration agreement between Genentech and Curis, GDC-0449 was discovered by Genentech and was jointly validated through a series of preclinical studies.
Genentech and Roche collaborate on the clinical development and commercialization of GDC-0449.
Curis is eligible to receive cash payments upon successful achievement of certain clinical development and regulatory approval milestones and royalties upon commercialization of GDC-0449.
CRIS is currently trading at $0.82, up 9 cents or 12.64%. DNA is currently trading at $76.70, up $2.32 or 3.12%.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.